old old OLD news. Exotic preclinical model.
eg old publication (and there are lots of them)- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940660/
How about the 2b study which is clearly unpublishable. (I wonder what the FDA experts thought of the report). Any body can guess why?. Why has phase 2a (dose response should have been done 10 years ago.) not started yet? Phase 3 cannot start until robust clinical outcome of 2a particularly in more severe OA.
If this 2a.study does not show breakthrough pain and function improvements in severe OA this P3 trial is waste of time.
Ann: PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL, page-12
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |